{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluorouracil+injection&page=2", "query": { "intervention": "Fluorouracil injection", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluorouracil+injection&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T03:47:08.425Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01227408", "title": "Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2009-02", "completion_date": "2011-02", "has_results": false, "last_update_posted_date": "2017-05-02", "last_synced_at": "2026-09-29T03:47:08.425Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01227408" }, { "nct_id": "NCT00069095", "title": "A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Oxaliplatin 130 mg/m^2", "type": "DRUG" }, { "name": "Capecitabine 1000 mg/m^2", "type": "DRUG" }, { "name": "Bevacizumab 7.5 mg/kg", "type": "DRUG" }, { "name": "Placebo for bevacizumab 7.5 mg/kg", "type": "DRUG" }, { "name": "Oxaliplatin 85 mg/m^2", "type": "DRUG" }, { "name": "Leucovorin 200 mg/m^2", "type": "DRUG" }, { "name": "Fluorouracil 400 mg/m^2", "type": "DRUG" }, { "name": "Bevacizumab 5 mg/kg", "type": "DRUG" }, { "name": "Placebo for bevacizumab 5 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2035, "start_date": "2003-07", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2016-10-06", "last_synced_at": "2026-09-29T03:47:08.425Z", "location_count": 49, "location_summary": "Berkeley, California • Fountain Valley, California • Fullerton, California + 44 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Gilroy", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00069095" }, { "nct_id": "NCT06385925", "title": "A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Neoplasm" ], "interventions": [ { "name": "TSN1611", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyligand Pharmaceuticals (Suzhou) Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 440, "start_date": "2024-04-29", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-09-29T03:47:08.425Z", "location_count": 3, "location_summary": "Houston, Texas • San Antonio, Texas • Fairfax, Virginia", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06385925" }, { "nct_id": "NCT02414165", "title": "The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Glioblastoma Multiforme", "Anaplastic Astrocytoma" ], "interventions": [ { "name": "Toca 511", "type": "BIOLOGICAL" }, { "name": "Toca FC", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Tocagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 403, "start_date": "2015-11-30", "completion_date": "2019-12-20", "has_results": false, "last_update_posted_date": "2020-02-07", "last_synced_at": "2026-09-29T03:47:08.425Z", "location_count": 50, "location_summary": "Phoenix, Arizona • Irvine, California • La Jolla, California + 41 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02414165" }, { "nct_id": "NCT00002570", "title": "Immediate Compared With Delayed Chemotherapy in Advanced Colorectal Cancer Without Signs or Symptoms of Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NCIC Clinical Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 67, "start_date": "1994-07-15", "completion_date": "2009-02-10", "has_results": false, "last_update_posted_date": "2020-04-06", "last_synced_at": "2026-09-29T03:47:08.425Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002570" }, { "nct_id": "NCT00983541", "title": "Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Brachytherapy or SBRT (Stereotactic body radiation therapy)", "type": "RADIATION" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2009-09", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2015-08-19", "last_synced_at": "2026-09-29T03:47:08.425Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00983541" }, { "nct_id": "NCT00911170", "title": "PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer", "Colon Cancer", "Colorectal Cancer", "Fever", "Locally Advanced", "Metastatic Colorectal Cancer", "Neutropenia", "Rectal Cancer" ], "interventions": [ { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Standard Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 847, "start_date": "2009-11-03", "completion_date": "2015-01-02", "has_results": true, "last_update_posted_date": "2017-12-29", "last_synced_at": "2026-09-29T03:47:08.425Z", "location_count": 72, "location_summary": "Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Modesto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00911170" }, { "nct_id": "NCT01322815", "title": "A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer" ], "interventions": [ { "name": "chemotherapy and GI-4000", "type": "DRUG" }, { "name": "GI-4000", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2010-10", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2016-08-15", "last_synced_at": "2026-09-29T03:47:08.425Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01322815" }, { "nct_id": "NCT03563170", "title": "QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma Non-resectable", "Hepatocellular Carcinoma Recurrent" ], "interventions": [ { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "haNK for infusion", "type": "BIOLOGICAL" }, { "name": "avelumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" }, { "name": "Aldoxorubicin hydrochloride", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "N-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-05-25", "completion_date": "2019-08-23", "has_results": false, "last_update_posted_date": "2021-03-18", "last_synced_at": "2026-09-29T03:47:08.425Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563170" }, { "nct_id": "NCT02826486", "title": "Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "BL-8040", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioLineRx, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2016-09", "completion_date": "2022-09-06", "has_results": true, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-09-29T03:47:08.425Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • New Orleans, Louisiana + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02826486" } ] }